Efficient derivation of chimeric-antigen receptor-modified T(SCM) cells

Chimeric-antigen receptor (CAR) T-cell immunotherapy employs autologous-T cells modified with an antigen-specific CAR. Current CAR-T manufacturing processes tend to yield products dominated by effector T cells and relatively small proportions of long-lived memory T cells. Those few cells are a so-ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Kranz, Emiko, Kuhlmann, Charles J., Chan, Joshua, Kim, Patrick Y., Chen, Irvin S. Y., Kamata, Masakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366550/
https://www.ncbi.nlm.nih.gov/pubmed/35967430
http://dx.doi.org/10.3389/fimmu.2022.877682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366550/
https://www.ncbi.nlm.nih.gov/pubmed/35967430
http://dx.doi.org/10.3389/fimmu.2022.877682

Ejemplares similares